Renin-Angiotensin-Aldosterone Inhibitors and COVID-19

Insights

Renin-angiotensin-aldosterone system (RAAS) blockers do not worsen COVID-19 outcomes. Continued use of RAAS blockers is recommended to prevent cardiovascular complications, especially in stable patients.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Concerns exist regarding renin-angiotensin-aldosterone system (RAAS) blockers and COVID-19 susceptibility.
  • RAAS blockers are crucial for managing various cardiovascular conditions.

Purpose of the Study:

  • To evaluate the impact of RAAS blockers on COVID-19 course.
  • To provide evidence-based recommendations on RAAS blocker use during the pandemic.

Main Methods:

  • Review of existing literature and clinical data.
  • Analysis of patient outcomes based on RAAS blocker treatment.

Main Results:

  • No evidence suggests RAAS blockers worsen COVID-19 severity.
  • Discontinuation of RAAS blockers may lead to worsening of cardiovascular comorbidities.

Conclusions:

  • RAAS blockers should be continued in patients with stable conditions.
  • The benefits of RAAS blockers in managing cardiovascular disease outweigh theoretical risks associated with COVID-19.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
743
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.1K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.2K